MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its... Read More

MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or... Read More

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc . (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients,... Read More

MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase... Read More

MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal Biomolecules , which describes the pharmacokinetic (PK) profile of a... Read More

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference happening... Read More

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results. “In the past quarter, our efforts were centered on driving enrollment... Read More

Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All patents are filed internationally, securing global coverage of buntanetap. MALVERN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical... Read More

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in... Read More

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the... Read More

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.... Read More

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. The first quarter was largely dedicated to the initiation of a pivotal... Read More

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. “Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3... Read More

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in... Read More

MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. "We are at a pivotal moment in our company’s journey as we have entered the... Read More

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results. In 2024, Annovis made significant progress by advancing the... Read More

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer’s & Parkinson’s Drug Development Summit happening on March 18-20 in Boston, MA. "This meeting represents an important... Read More

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork , a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio’s (NYSE: ANVS) recent feature on Today’s Marketplace (TMP) as part of its commitment to amplifying industry leaders’ voices through targeted distribution channels. The full interview can be viewed at... Read More

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue:... Read More

MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients... Read More

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in... Read More

MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps. Dear Friends, The last... Read More

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein... Read More

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results. Fourth Quarter 2023 Highlights Clinical Updates Announced Last Patient Last Visit in the Phase III Study of... Read More

Buntanetap lowers the levels of TDP43, NfL, and GFAP BERWYN, Pa. / Nov 02, 2023 / Business Wire / Recent developments in biomarker research have enabled the performance of measurements of important biomarkers in plasma rather than in CSF (cerebrospinal fluid), making it possible to follow the changes in biomarkers during the... Read More

BERWYN, Pa. / Oct 31, 2023 / Business Wire / Annovis Bio, Inc . (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced the pricing of an underwritten public offering of 1,250,000 units consisting of (i) one share of its common stock and (ii) an accompanying warrant... Read More

BERWYN, Pa. / Oct 30, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) an accompanying warrant to... Read More

BERWYN, Pa. / Oct 30, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The feedback from the DSMB was: no drug-related SAEs (Serious Adverse... Read More

BERWYN, Pa. / Oct 24, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27. Neurotoxic... Read More

BERWYN, Pa. / Aug 15, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments. Second Quarter 2023 Highlights and New Developments... Read More

BERWYN, Pa. / Jul 18, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), presented three posters at the Alzheimer’s Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16-20.... Read More

The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug BERWYN, Pa. / Jun 27, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS), a clinical stage drug platform company developing novel and transformative therapies for neurodegenerative diseases, announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition... Read More

The drug is proving to be safe and well-tolerated BERWYN, PA. / Jun 20, 2023 / Business Wire / Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinson’s Disease (PD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The feedback from the DSMB was: no... Read More

BERWYN, Pa. , June 8, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) and developing novel and transformative therapies, announced that its PD phase III study of its lead compound buntanetap has reached full enrollment in a record nine months after it began. Since the first patient was dosed... Read More

BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments. First Quarter 2023 Highlights and New Developments Clinical Updates At a recent R&D webcast on April 20, 2023, the Company:... Read More

BERWYN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a patent with claims covering the use of Annovis Bio’s lead drug candidate, buntanetap, for the prevention and treatment of diseases... Read More

Company to hold R&D webcast today at 4:00 pm ET to review ongoing clinical programs in Alzheimer's disease and Parkinson's disease Updated Webcast link and dial-in information are provided below BERWYN, Penn. , April 20, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases is providing an updated link and dial-in... Read More

Phase 2/3 AD Study continues to make steady progress in patient recruitment Company to hold R&D webcast on Thursday, April 20 th to review ongoing clinical programs in Alzheimer's disease and Parkinson's disease BERWYN, Pa. , April 19, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that patient... Read More

Webcast to be held on Thursday, April 20 th at 4pm EDT . BERWYN, Pa. , April 13, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will hold a live R&D webcast to review its clinical development programs in Alzheimer's disease and Parkinson's disease. As part of the presentation, the... Read More

BERWYN, Pa. , April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that in the last week it has raised aggregate gross proceeds of approximately $8.7 million between its now-terminated at–the-market program and a private placement to individual members of its Board of Directors and management.... Read More

BERWYN, Pa. , April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed recent accomplishments. Fourth Quarter Highlights and New Developments Received approval for European Union clinical trial sites... Read More

BERWYN, Pa. , March 22, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD ™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023 , in Gothenburg, Sweden . The... Read More

BERWYN, Penn. , Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology. Maria L. Maccecchini, Ph.D.,... Read More

Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in New York City. Presentation Details Presentation time: 9:00 am ET to 9:30 am ET Date: October 26, 2022 Location: The Mandarin Oriental Hotel in New York City Webcast Link:... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer's Disease . The published study, titled ' Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD). Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company... Read More

Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022 , in New York City . Presentation Details Presentation time: 12:30 p.m. to 12:55 p.m. Eastern Time Date: September 29 , 2022 Location: Sofitel Hotel, 45 West 44th Street, New York (Track... Read More

Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 ( link ), US11376238 ( link ), and US11382893 ( link ). The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap. They will provide intellectual... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer Dr. Maria Maccecchini . Dear Fellow Stockholder, Over the years we have been talking about the potential of buntanetap to treat more than Alzheimer's disease. In cell models, animal models and human... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately. Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD) has been dosed. The Phase 3 trial is a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap.... Read More

Annovis Bio, Inc . (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financial results for the quarter ended June 30, 2022 , and reviewed recent accomplishments. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "Because of buntanetap's unique mode of action, it has the potential to act on a... Read More

The Panel will be Moderated by Jeffrey Cummings , MD, ScD, and Krista Lanctôt, Ph.D. Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, will be participating on the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International... Read More

Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings , MD, ScD, and Krista Lanctôt, Ph.D. Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that Maria Maccecchini, Ph.D., Founder, President, and CEO,... Read More

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the Company received notice from the FDA that the Phase 3 clinical study in early Parkinson's patients may proceed. The FDA accepted the... Read More

Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries Annovis Bio (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that the... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, "we have made significant progress advancing buntanetap in Parkinson's disease and... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), a part of the National Institutes of Health. Under this CRADA, NIA and Annovis will collaborate to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating... Read More

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Maria L. Maccecchini, Ph.D. has been named as a... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, is pleased to participate in World Parkinson's Day to promote greater awareness of how Parkinson's disease affects those living with the progressive disease and support research efforts to develop disease-modifying treatment options. An estimated one million people in the U.S. and more... Read More

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th. Management will present an update on business activities. The pre-recorded presentation can be viewed during the days of... Read More